Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2016 Jun 1;157(3):461–474. doi: 10.1007/s10549-016-3839-3

Figure 5. Higher frequency of proliferating tumor cells at the region adjacent to the biopsy wound than in distant areas of the tumor.

Figure 5

(A) IHC of human breast tissue for Ki67 marker in the region adjacent to the biopsy wound (adjacent) and the region distant to the biopsy wound (distant). The images from 40x magnification (left panels) and 400x magnification (right panels) of the 40x-red labeled area are shown. Scale bars are shown. BW, biopsy wound. (B) IHC of the same tissue sample from (A) with AE1/AE3 antibody as a marker for cytokeratin in the region adjacent to the biopsy (adjacent). The images from 40x magnification (left panels) and 400x magnification (right panels) of the 40x-red labeled area are shown. (C) Percentage of Ki67 positive cells (relative to all cancer cells present in the analyzed fields) in invasive tumor in breast cancer samples in regions adjacent and distant to the biopsy wound (n= 30), p=0.009, using a paired student’s t test analysis. (D) Percentage of Ki67 positive tumor cells in the tumor in the region adjacent to the biopsy as a function of time (days) between the core needle biopsy procedure and surgical excision of the breast tissue (n=30), p=0.97, using a regression analysis.